Is Celestica The Best AI Stock to Buy Now?
Technology and hardware business Celestica (NYSE:CLS) has seen massive upward…
Sell
27
ALGS Quote, Financials, Valuation and Earnings
Last price:
$7.00
Seasonality move
:
-25.49%
Day range:
$6.56 - $7.30
52-week range:
$3.76 - $13.69
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
31.99x
P/B ratio:
0.81x
Volume:
37.3K
Avg. volume:
48.8K
1-year change:
-45.71%
Market cap:
$43.2M
Revenue:
$2.2M
EPS (TTM):
-$8.60
Analysts' Opinion
-
Consensus RatingAligos Therapeutics, Inc. has received a consensus rating of Buy. The company's average rating is a Buy based on 4 Buy ratings, 0 Hold ratings, and 0 Sell ratings.
-
Price Target UpsideAccording to analysts' consensus price target of $68.20, Aligos Therapeutics, Inc. has an estimated upside of 870.82% from its current price of $7.03.
-
Price Target DownsideAccording to analysts, the lowest downside price target is $20.00 representing 100% downside risk from its current price of $7.03.
Fair Value
-
According to the consensus of 4 analysts, Aligos Therapeutics, Inc. has 870.82% upside to fair value with a price target of $68.20 per share.
ALGS vs. S&P 500
-
Over the past 5 trading days, Aligos Therapeutics, Inc. has overperformed the S&P 500 by 2.94% suggesting its relative strength compared to the major market average is strong at this time.
Share Buyback
-
Aligos Therapeutics, Inc. does have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.
Revenue Growth
-
Aligos Therapeutics, Inc. revenues have been falling on a year-over-year basis for 10 quarters in a row. In the most recent quarter Aligos Therapeutics, Inc. reported revenues of $169K.
Earnings Growth
-
Aligos Therapeutics, Inc. has grown year-over-year earnings for 2 quarters straight. In the most recent quarter Aligos Therapeutics, Inc. reported earnings per share of -$1.91.
Enterprise value:
-29.5M
EV / Invested capital:
-0.50x
Price / LTM sales:
31.99x
EV / EBIT:
--
EV / Revenue:
-13.48x
PEG ratio (5yr expected):
-0.01x
EV / Free cash flow:
0.36x
Price / Operating cash flow:
--
Enterprise value / EBITDA:
--
Gross Profit (TTM):
$1.3M
Return On Assets:
-21.73%
Net Income Margin (TTM):
-1106.73%
Return On Equity:
-38.44%
Return On Invested Capital:
-34.65%
Operating Margin:
-12907.69%
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-12-31 | 2024-12-31 | 2025-12-31 | 2024-12-31 | 2025-12-31 | |
| Income Statement | ||||||
| Revenue | $15.5M | $3.9M | $2.2M | $629K | $169K | |
| Gross Profit | $12.5M | $1.3M | $1.3M | -$42K | -$88K | |
| Operating Income | -$88.1M | -$89.2M | -$88M | -$20.6M | -$21.8M | |
| EBITDA | -$85.1M | -$86.5M | -$87.1M | -$19.9M | -$21.6M | |
| Diluted EPS | -$5.50 | -$20.92 | -$8.60 | -$13.08 | -$1.91 | |
| Period Ending | 2021-12-31 | 2022-12-31 | 2023-12-31 | 2024-12-31 | 2025-12-31 | |
|---|---|---|---|---|---|---|
| Balance Sheet | ||||||
| Current Assets | $204.4M | $133.5M | $141.1M | $62.1M | $82.9M | |
| Total Assets | $239.1M | $149.9M | $153.9M | $71.9M | $89.6M | |
| Current Liabilities | $39M | $33.1M | $23.9M | $21.7M | $21.2M | |
| Total Liabilities | $54.4M | $46M | $61.8M | $100.8M | $36M | |
| Total Equity | $184.7M | $103.9M | $92.1M | -$29M | $53.5M | |
| Total Debt | $11.7M | $9.5M | $7.9M | $5M | $1.7M | |
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-12-31 | 2024-12-31 | 2025-12-31 | 2024-12-31 | 2025-12-31 | |
| Cash Flow Statement | ||||||
| Cash Flow Operations | -$79M | -$80.7M | -$82.5M | -$18.4M | -$21.7M | |
| Cash From Investing | $45M | -$18.3M | -$37.8M | $20M | -$2M | |
| Cash From Financing | $88.3M | $355K | $101.6M | $97K | $123K | |
| Free Cash Flow | -$79M | -$80.9M | -$82.9M | -$18.4M | -$21.8M | |
ALGS
Sector
Market Cap
$43.2M
$25.7M
Price % of 52-Week High
51.32%
50%
Dividend Yield
0%
0%
Shareholder Yield
-175.88%
-1.64%
1-Year Price Total Return
-45.71%
-18.75%
Beta (5-Year)
2.671
0.490
Dividend yield:
0%
Annualized payout:
$0.00
Payout ratio:
--
Growth streak:
0 years
Technicals
8-day SMA
Buy
Level
$6.98
200-day SMA
Sell
Level
$8.61
Bollinger Bands (100)
Sell
Level
7.11 - 10.15
Chaikin Money Flow
Sell
Level
-103.3K
20-day SMA
Buy
Level
$7.00
Relative Strength Index (RSI14)
Sell
Level
46.07
ADX Line
Sell
Level
12.7
Williams %R
Neutral
Level
-39.916
50-day SMA
Sell
Level
$7.95
MACD (12, 26)
Sell
Level
-0.28
25-day Aroon Oscillator
Sell
Level
-40
On Balance Volume
Neutral
Level
5.1M
Financial Scores
Sell
Altman Z-Score
(Annual)
Level (-11.4727)
Sell
CA Score
(Annual)
Level (-6.966)
Sell
Beneish M-Score
(Annual)
Level (-1.066)
Sell
Momentum Score
Level (1)
Sell
Ohlson Score
Level (4.2618)
Buy
Piotroski F Score
(Annual)
Level (4)
Sell
Quality Ratio Score
Level (2)
Sell
Fundamental Score
Level (2)
Revenue Forecast
Earnings per Share Forecast
Company Profile
Aligos Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the provision of therapeutics for chronic liver diseases and viral infections. The firm is focused on the discovery and development of targeted antiviral therapies for chronic hepatitis B (CHB) and coronaviruses, as well as leveraging its expertise in liver diseases to create targeted therapeutics for nonalcoholic steatohepatitis (NASH). The company was founded by Lucinda Quan and Lawrence M. Blatt on February 5, 2018 and is headquartered in South San Francisco, CA.
Stock Forecast FAQ
In the current month, ALGS has received 4 Buy ratings 0 Hold ratings, and 0 Sell ratings. The ALGS average analyst price target in the past 3 months is $68.20.
-
Where Will Aligos Therapeutics, Inc. Stock Be In 1 Year?
According to analysts, the consensus estimate is that Aligos Therapeutics, Inc. share price will rise to $68.20 per share over the next 12 months.
-
What Do Analysts Say About Aligos Therapeutics, Inc.?
Analysts are divided on their view about Aligos Therapeutics, Inc. share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that Aligos Therapeutics, Inc. is a Sell and believe this share price will drop from its current level to $20.00.
-
What Is Aligos Therapeutics, Inc.'s Price Target?
The price target for Aligos Therapeutics, Inc. over the next 1-year time period is forecast to be $68.20 according to 4 Wall Street analysts, 4 of them rate the stock a Buy, 0 rate the stock a Sell, and 0 analysts rate the stock a Hold.
-
Is ALGS A Buy, Sell Or Hold?
According to Wall Street analysts, the consensus rating for Aligos Therapeutics, Inc. is a Buy. 4 of 4 analysts rate the stock a Buy at this time.
-
How Can I Buy Shares Of ALGS?
You can purchase shares of Aligos Therapeutics, Inc. via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase Aligos Therapeutics, Inc. shares.
-
What Is The Aligos Therapeutics, Inc. Share Price Today?
Aligos Therapeutics, Inc. was last trading at $7.00 per share. This represents the most recent stock quote for Aligos Therapeutics, Inc.. Yesterday, Aligos Therapeutics, Inc. closed at $7.03 per share.
-
How To Buy Aligos Therapeutics, Inc. Stock Online?
In order to purchase Aligos Therapeutics, Inc. stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.
Get ALGS Stock Alert
Signup to receive the latest stock alerts
Financial Ratios
ALGS
Sector
P/E ratio
--
22.00x
PEG ratio
-0.01x
-0.01x
P/B ratio
0.81x
1.78x
Price / LTM sales
31.99x
1.49x
Growth Metrics
ALGS
Sector
Revenue growth
-73.13%
3.28%
Earnings growth
85.36%
12%
Revenue (5-year growth)
--
6.3%
Earnings forecast
-$2.49
-$0.20
Profitability
ALGS
Sector
Profitability FY 2025
$1.3M
$2.4M
Return on invested capital
-34.65%
-33.43%
Return on assets
-21.73%
-30.04%
Return on equity
-38.44%
-40.01%
Earnings Date
Last Earnings Date
Mar
5
Next Earnings Date
May
5
Estimated Next Earnings Date
Jun
4
Balance Sheet
ALGS
Sector
Total cash
$78M
$24.1M
Short term investments
$19.9M
$23.2M
Total assets
$89.6M
$69.8M
Long term debt
$1.7M
$2.5M
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Will AI Disrupt SaaS Software Stocks?
Since January 28th, software stocks in the United States have…
Why Is Meta Stock Going Higher?
Over the last five days, shares of Instagram and Facebook…
Stock Ideas
Sell
49
Is NVDA Stock a Buy?
Market Cap: $4.4T
P/E Ratio: 37x
Sell
45
Is AAPL Stock a Buy?
Market Cap: $3.8T
P/E Ratio: 35x
Sell
37
Is GOOGL Stock a Buy?
Market Cap: $3.7T
P/E Ratio: 28x
Alerts
Buy
68
XENE alert for Mar 10
Xenon Pharmaceuticals, Inc. [XENE] is down 3.44% over the past day.
Sell
32
BNTX alert for Mar 10
BioNTech SE [BNTX] is down 17.94% over the past day.
Buy
52
MLAB alert for Mar 10
Mesa Laboratories, Inc. [MLAB] is down 16.06% over the past day.
THE #1 STOCK ANALYSIS TOOL
TO MAKE SMARTER BUY AND SELL DECISIONS
Show me the best stock
